Enzene gets DCGI nod for biosimilar drug to treat haematological disorder
Tuesday, September 14, 2021, 21:03
The symptoms of this disorder ranges from mild skin bleeding and bruises to potentially fatal internal bleeding, such as in the gastrointestinal tract and the brain.
Powered by WPeMatico
You can follow any responses to this entry through the
RSS 2.0 feed.
Both comments and pings are currently closed.
Comments are closed for this story.